Because our molecular lab includes a normal control using blood lymphocytes, we can rule out the possibility that the patient’s CLL harbored either a BRAF or an NRAS mutation, and, thus, this did not confound the results. The gene discussed is NRAS; the disease is B-cell chronic lymphocytic leukemia.